DocWire News Editors

DocwireNews

As biosimilars continue to integrate into pharmacologic arsenals around the world, they are expected to abate medical expenses, allowing patients to access the drug therapies needed for treatment. In this review, published in Science Direct, authors introduced the concept of biosimilar development as well as pharmacokinetic (PK) data, which they obtained via clinical and non-clinical studies of biosimilar therapy, while also providing some future perspectives on biosimilar monoclonal antibodies (mAbs).Biosimilars were conceptualized in the early 2000s in the European Union (EU), with current regulations for biosimilars existing in the United States and Japan, among other nations. The initial biosimilar mAb to receive approval was the biosimilar for infliximab, a biologic that is used for treating rheumatoid arthritis (RA), psoriatic arthritis (PA), Crohn&rsquo;s disease (CD), and ulcerative colitis (UC), to name a few. As of September 2018, biosimilars for adalimumab, rituximab, bevacizumab, and trastuzumab, and etanercept have also passed the approval process, with biosimilars for ranibizumab and omalizumab in the developmental stage.The development phase of manufacturing any biosimilar is stringent, as the product is extensively tested up against its original reference. In creating a biosimilar, the company must first establish the manufacturing process, ensuring that the reference product goes undisclosed, making the process quite different from that of an originator product. However, any biosimilar must be highly comparable to the referenced product as it pertains to attributes such as structure, physiochemical and biological properties. The drug&rsquo;s developers must justify any deviations in quality attributes to ensure there are no clinical differences between the biosimilar and the reference drug in terms of efficacy and safety.For the assessment the comparability of any biosimilar to the original product, a stepwise approach is often implemented consisting of comparative quality, clinical, and non-clinical studies. Because the formulation of the biosimilar is not identical to that of the reference, differences are usually discovered in the comparative quality testing phase, and subsequently, in in vitro or in vivo clinical studies conducted to ensure that safety and efficacy.An integral part in developing any biosimilar is the clinical PK profile, which is usually the first step in the comparative clinical study.&nbsp; Potential PK-related quality attributes include isoelectric point, charge variant contents and glycan structure and antigen binding, the latter of which can affect the PK profile by accelerating the clearance of immune complexes. For the inaugural mAb biosimilar of infliximab (CT-P13), PK efficacy and safety were concomitantly studied in the patient population. In two clinical trials, results indicated that the differences in quality attributes between the reference product and biosimilar had little impact on their PK, exhibiting a favorable comparability with the biosimilar next to its originator.The increased future development of biosimilar mAbs is expected to lessen health care expenditures, thus facilitating an easier path for patients to access and purchase the medicines they need. In 2018, the FDA released the Biosimilar Action Plan, intended to foster innovation and competition among biologics while spurring the development of more biosimilars. Concluding their review, the authors remarked that from a scientific viewpoint, &ldquo;elucidating the factors regulating the PK profile of mAbs and other biologics in humans may contribute to more efficient development of biosimilars and next generation innovative mAbs.&rdquo;

Brandon Twyford

DESTINY-Breast09 Demonstrates First-Line Superiority of Enhertu Plus Pertuzumab in HER2-Positive Metastatic Breast Cancer

HER2 Breast Cancer

Trodelvy Plus Keytruda Significantly Improves Progression-Free Survival in PD-L1+ mTNBC, Phase III Data Show

Triple-Negative Breast Cancer

Jordana Jampel

Actress Michelle Trachtenberg's Premature Death From Diabetes Reveals Dangers of Chronic Complications

Diabetes

Latest News

Biosimilarity Assessment of Biosimilar Therapeutic Monoclonal Antibodies

Rheumatology

As biosimilars continue to integrate into pharmacologic arsenals around the world, they are expected to abate medical expenses, allowing patients to access the drug therapies ...

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HR Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Ophthalmology

— Demodex Blepharitis

Neurology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe